Mentions
Extended reach
Total likes
Video views
AI synopsis
The overall tone indicates a high level of interest, with many commenters referencing successful trial results and potential new treatments, evidenced by phrases like 'good news,' 'positive results,' and 'high response rates.' The tone shifts slightly with some posts expressing cautious optimism or skepticism, especially regarding side effects like herpes zoster, which reflects a nuanced view on the trial's impact and significance.
Most discussions show support or positive recognition of the trial's findings, reflecting consensus about the potential of anifrolumab, despite some expressed uncertainties.
The posts demonstrate high interest in the research, with multiple references to trial outcomes, drug development, and clinical implications.
Participants show moderate engagement, sharing detailed information, citing specific trials like TULIP-2, and discussing side effects and future potential.
The discussions suggest a moderate to high impact, highlighting the importance of these findings for future SLE therapies, though some remain cautious or awaiting further evidence.
Original Article: Trial of Anifrolumab in Active Systemic Lupus Erythematosus https://t.co/PwZnsYSu2F
A phase 3 trial of anifrolumab, a monoclonal antibody to type I interferon receptor subunit 1, showed benefit in a composite primary end point of lupus scores. https://t.co/PwZnsYSu2F
18 years after the discovery that type I interferon is a key molecular target in patients with lupus (Blanco, Science, 2001), a randomized trial shows that Anifrolumab is effective in SLE. A very good illustration of translational science https://t.co/2mXHYHeAtZ
Original Article: Trial of Anifrolumab in Active Systemic Lupus Erythematosus https://t.co/PwZnsZa4Ud
Listen to our new podcast from the #ACR2019 with Eric Morand about #Anifrolumab in #SLE - the #TULIP-2 study - whilst preparing for the turn of the year.
When you have an under-researched chronic illness like #MECFS, a large, well-designed, pharma-funded trial of a treatment for a dynamically disabling disease is a marvel to behold. High quality evidence from rigorous trials can’t come soon enough. https://t.co/tcsMDdixm5
This video discusses the recent FDA approval of anifrolumab for lupus. It covers clinical trial results, including differences between Phase II and Phase III outcomes, and highlights the drug's efficacy in certain…
Tulip2 trials
RT @chriswincup: And there is good news! ⭐️ Clinical trials are starting to show successful use of targeted therapies. Most recently with…
And there is good news! ⭐️ Clinical trials are starting to show successful use of targeted therapies. Most recently with the positive Phase III for Anifrolumab by @EricFMorand et al This means we may be better at achieving those targets in the future
https://t.co/oUncRnd5th
9/ Please find below the specific side effects of TULIP, TULIP-LN, and a sub-analysis of the WGET trial. https://t.co/4oVzZXuJSm https://t.co/eN4jgLPIBn https://t.co/AyH2hY4dd9
New drugs in the pipeline for CLE - https://t.co/ytFAbRilUE https://t.co/ZepRJuf4Nl https://t.co/JE5vjPuYmH
Anifrolumab is efficacious for CLE but currently only approved for SLE - https://t.co/ZepRJuf4Nl
When you have an under-researched chronic illness like #MECFS, a large, well-designed, pharma-funded trial of a treatment for a dynamically disabling disease is a marvel to behold. High quality evidence from rigorous trials can’t come soon enough. https://t.co/tcsMDdixm5
Thx for example. This is an online-only supplement. Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus. Supplement 2. N Engl J Med. 2020;382:211-221. Access date. URL https://t.co/7aho7wVDow
RT @davidvanduin: Dr Fernandez Ruiz now covers anifrolumab (anti-interferon receptor) for SLE. ⬆️⬆️⬆️ risk of H. zoster #ECCMID2022 http…
RT @davidvanduin: Dr Fernandez Ruiz now covers anifrolumab (anti-interferon receptor) for SLE. ⬆️⬆️⬆️ risk of H. zoster #ECCMID2022 http…
Dr Fernandez Ruiz now covers anifrolumab (anti-interferon receptor) for SLE. ⬆️⬆️⬆️ risk of H. zoster #ECCMID2022 https://t.co/LUGK6Vnh0s
#086 Trial of Anifrolumab in Active Systemic Lupus Erythematosus N Engl J Med 2020;382:211-21. TULIP-2試験 活動性のSLEに対するアニフロルマブは、プラセボと比較して、52週後の奏効（BICLAで評価）を認める割合が高かった
RT @JesusLoarce: 1) Trial of Anifrolumab in Active Systemic Lupus Erythematosus (TULIP-2) ➡️Phase III, randomized, placebo-controlled trial…
RT @JesusLoarce: 1) Trial of Anifrolumab in Active Systemic Lupus Erythematosus (TULIP-2) ➡️Phase III, randomized, placebo-controlled trial…
RT @JesusLoarce: 1) Trial of Anifrolumab in Active Systemic Lupus Erythematosus (TULIP-2) ➡️Phase III, randomized, placebo-controlled trial…
RT @JesusLoarce: 1) Trial of Anifrolumab in Active Systemic Lupus Erythematosus (TULIP-2) ➡️Phase III, randomized, placebo-controlled trial…
RT @JesusLoarce: 1) Trial of Anifrolumab in Active Systemic Lupus Erythematosus (TULIP-2) ➡️Phase III, randomized, placebo-controlled trial…
RT @JesusLoarce: 1) Trial of Anifrolumab in Active Systemic Lupus Erythematosus (TULIP-2) ➡️Phase III, randomized, placebo-controlled trial…
1) Trial of Anifrolumab in Active Systemic Lupus Erythematosus (TULIP-2) ➡️Phase III, randomized, placebo-controlled trial. 52 weeks. ➡️Recently approved by the FDA. https://t.co/39fOoqu6GK https://t.co/thzegczmG4 #Lupus #Rheumatology
MUSE trial https://t.co/bKjstSMrsp TULIP-I trial https://t.co/rDtUn1f20D TULIP-II trial https://t.co/zEkWRTs9Sa
昨日FDAがSLEに認可。AnifrolumabはI型インターフェロン受容体に対する抗体です。SLEの複合活動性指標BICLAの改善が示されています。IFNシグナチャーが明らかな患者さんで有効率高し。副作用は感染症特に帯状疱疹。PMID: 31851795 https://t.co/WrJtmHo09l
@PearlF @anandcpatelmdms Doesn't look like there was a big difference in response in those with high vs low interferons in Tulip 2 https://t.co/r63CKBzajN https://t.co/v7U0Bgx0r8
This was followed by yet more good news from trials in #SLE
RT @rheum_cat: @JYazdanyMD ⭐SLE trials, both positive
RT @rheum_cat: @JYazdanyMD ⭐SLE trials, both positive
RT @rheum_cat: @JYazdanyMD ⭐SLE trials, both positive
RT @rheum_cat: @JYazdanyMD ⭐SLE trials, both positive
@JYazdanyMD ⭐SLE trials, both positive
RT @PA_Maday: TULIP-2 Trial Trial of Anifrolumab in Active Systemic Lupus Erythematosus https://t.co/DfvQhUJ0ov https://t.co/eFVNHcB7E3
TULIP-2 Trial Trial of Anifrolumab in Active Systemic Lupus Erythematosus https://t.co/DfvQhUJ0ov https://t.co/eFVNHcB7E3
The articles we will be discussing tonight are the results from TULIP 1 (https://t.co/JQEwuqnpxS) and TULIP 2 (https://t.co/osuoj9zKos). #RheumJC
Trial of Anifrolumab in Active Systemic Lupus Erythematosus. https://t.co/iqTDwTcPVn
This study turned the secondary outcome of TULIP 1 to primary outcome. 1:1 ratio to anifrolumab 300 mg vs placebo x 48 weeks. Primary end point was BICLA. Reached primary end point as 47.8% patients in anifrolumab group had response vs 31.5%. #UMKCRCT https://t.co/tQO26yd4xM
Trial of Anifrolumab in Active Systemic Lupus Erythematosus | NEJM https://t.co/9IsqKeeuQ8 https://t.co/xaMIpFVVZY
This trial also highlights the importance of development and rigorous validation of outcome measures that are reliable and sensitive to change as they affect the outcome of million dollar trials and approval of drugs that can benefit our patients-TULIP2 https://t.co/KQNi6BZfa2
RT @NatRevRheumatol: #ResearchHighlight | Positive results for anifrolumab in phase III SLE trial #lupus #TULIP2 #anifrolumab #therapy #rh…
RT @NatRevRheumatol: #ResearchHighlight | Positive results for anifrolumab in phase III SLE trial #lupus #TULIP2 #anifrolumab #therapy #rh…
#ResearchHighlight | Positive results for anifrolumab in phase III SLE trial #lupus #TULIP2 #anifrolumab #therapy #rheumtwitter Read the original research from @NEJM here https://t.co/wcadoAfDie Read our #news story here https://t.co/zQ1PsrVLAd
https://t.co/FNwzLP0ui1
RT @NEJM: Original Article: Trial of Anifrolumab in Active Systemic Lupus Erythematosus https://t.co/PwZnsZa4Ud
Bummer https://t.co/ONEEYOpuN6
抄読会より I型インターフェロン受容体抗体AnifrolumabのSLEにおける有用性が示された。ステロイド減量効果有。新しいお薬になりそうです Trial of Anifrolumab in Active Systemic Lupus Erythematosus | NEJM https://t.co/5KPiB7posx #SLE #ステロイド #anifrolumab #膠原病
RT @NEJM: Original Article: Trial of Anifrolumab in Active Systemic Lupus Erythematosus https://t.co/PwZnsZa4Ud
RT @NEJM: Original Article: Trial of Anifrolumab in Active Systemic Lupus Erythematosus https://t.co/PwZnsZa4Ud
RT @NEJM: Original Article: Trial of Anifrolumab in Active Systemic Lupus Erythematosus https://t.co/PwZnsZa4Ud
RT @NEJM: Original Article: Trial of Anifrolumab in Active Systemic Lupus Erythematosus https://t.co/PwZnsZa4Ud
RT @NEJM: Original Article: Trial of Anifrolumab in Active Systemic Lupus Erythematosus https://t.co/PwZnsZa4Ud
RT @NEJM: Original Article: Trial of Anifrolumab in Active Systemic Lupus Erythematosus https://t.co/PwZnsZa4Ud
RT @NEJM: Original Article: Trial of Anifrolumab in Active Systemic Lupus Erythematosus https://t.co/PwZnsZa4Ud
RT @NEJM: Original Article: Trial of Anifrolumab in Active Systemic Lupus Erythematosus https://t.co/PwZnsZa4Ud
RT @lastweekinmed: Monthly anifrolumab resulted in a higher percentage of patients with a response at week 52 than did placebo. The frequen…
RT @sebasugarte: Artículo original: Ensayo de anifrolumab en lupus eritematoso sistémico activo https://t.co/VNPvXem28o
RT @NEJM: Original Article: Trial of Anifrolumab in Active Systemic Lupus Erythematosus https://t.co/PwZnsZa4Ud
RT @NEJM: Original Article: Trial of Anifrolumab in Active Systemic Lupus Erythematosus https://t.co/PwZnsZa4Ud
RT @NEJM: Original Article: Trial of Anifrolumab in Active Systemic Lupus Erythematosus https://t.co/PwZnsZa4Ud
Artículo original: Ensayo de anifrolumab en lupus eritematoso sistémico activo https://t.co/VNPvXem28o
RT @NEJM: Original Article: Trial of Anifrolumab in Active Systemic Lupus Erythematosus https://t.co/PwZnsZa4Ud
RT @NEJM: Original Article: Trial of Anifrolumab in Active Systemic Lupus Erythematosus https://t.co/PwZnsZa4Ud
Original Article: Trial of Anifrolumab in Active Systemic Lupus Erythematosus https://t.co/PwZnsZa4Ud
31 % response with placebo!! One of the highest ever. Speaks a lot about disease biology Trial of Anifrolumab in Active Systemic Lupus Erythematosus | NEJM https://t.co/uhk0MC0ro2
RT @jlandreu2014: Nueva autorización en ciernes para #Lupus Gran noticia. @Felupus @SEReumatologia @SORCOM1 https://t.co/oxHU0uHckd
活動性の全身性エリテマトーデスに対するアニフロルマブの試験 Trial of Anifrolumab in Active Systemic Lupus Erythematosus N Engl J Med 2020; 382:211-221 https://t.co/xR8sl7SBSM
Trial of Anifrolumab in Active Systemic Lupus Erythematosus | NEJM https://t.co/x3JLRByHWC
RT @farmaciaclinico: Trial of Anifrolumab in Active Systemic #Lupus Erythematosus @NEJM https://t.co/nNgL16lGvP
Trial of Anifrolumab in Active Systemic #Lupus Erythematosus @NEJM https://t.co/nNgL16lGvP
La administración mensual de anifrolumab resultaría en un mayor porcentaje de pacientes con una respuesta en la semana 52. La frecuencia de herpes zóster sería mayor con anifrolumab https://t.co/rRuK9s1ycv
Trial of Anifrolumab in Active Systemic Lupus Erythematosus | NEJM "The frequency of herpes zoster was higher with anifrolumab than with placebo." https://t.co/MVzRyGa4GU
RT @Tuhina_Neogi: Anifrolumab in #SLE. Two trials. Two different primary outcomes. Two different results. This one was positive: https://t.…
RT @NEJM: A phase 3 trial of anifrolumab, a monoclonal antibody to type I interferon receptor subunit 1, showed benefit in a composite prim…
RT @NEJM: A phase 3 trial of anifrolumab, a monoclonal antibody to type I interferon receptor subunit 1, showed benefit in a composite prim…
Anifrolumab in #SLE. Two trials. Two different primary outcomes. Two different results. This one was positive: https://t.co/vqWOQlMikK https://t.co/qPhoPFGvzJ
RT @NEJM: A phase 3 trial of anifrolumab, a monoclonal antibody to type I interferon receptor subunit 1, showed benefit in a composite prim…
RT @NEJM: A phase 3 trial of anifrolumab, a monoclonal antibody to type I interferon receptor subunit 1, showed benefit in a composite prim…
RT @NEJM: A phase 3 trial of anifrolumab, a monoclonal antibody to type I interferon receptor subunit 1, showed benefit in a composite prim…
RT @NEJM: A phase 3 trial of anifrolumab, a monoclonal antibody to type I interferon receptor subunit 1, showed benefit in a composite prim…
RT @NEJM: A phase 3 trial of anifrolumab, a monoclonal antibody to type I interferon receptor subunit 1, showed benefit in a composite prim…
RT @NEJM: A phase 3 trial of anifrolumab, a monoclonal antibody to type I interferon receptor subunit 1, showed benefit in a composite prim…
A phase 3 trial of anifrolumab, a monoclonal antibody to type I interferon receptor subunit 1, showed benefit in a composite primary end point of lupus scores. https://t.co/PwZnsYSu2F
RT @Yohei_Kanzawa: マブは追いつけなくなってきました。SLE治療薬、Ⅰ型インターフェロン受容体抗体、アニフロマブ anifromabのRCT。#SLE Trial of Anifrolumab in Active Systemic Lupus Erythema…
RT @FAndreMD: 18 years after the discovery that type I interferon is a key molecular target in patients with lupus (Blanco, Science, 2001),…
Trial of anifrolumab in active systemic lupus erythematosus https://t.co/nt0WzXNCVy #m3india
Trial of Anifrolumab in Active Systemic Lupus Erythematosus | NEJM #アニフロルマブ #anifrolumab https://t.co/SqWGBywkEb
RT @ARD_BMJ: Listen to our new podcast from the #ACR2019 with Eric Morand about #Anifrolumab in #SLE - the #TULIP-2 study - whilst preparin…
RT @ARD_BMJ: Listen to our new podcast from the #ACR2019 with Eric Morand about #Anifrolumab in #SLE - the #TULIP-2 study - whilst preparin…
RT @ARD_BMJ: Listen to our new podcast from the #ACR2019 with Eric Morand about #Anifrolumab in #SLE - the #TULIP-2 study - whilst preparin…
RT @ARD_BMJ: Listen to our new podcast from the #ACR2019 with Eric Morand about #Anifrolumab in #SLE - the #TULIP-2 study - whilst preparin…
RT @ARD_BMJ: Listen to our new podcast from the #ACR2019 with Eric Morand about #Anifrolumab in #SLE - the #TULIP-2 study - whilst preparin…
Listen to our new podcast from the #ACR2019 with Eric Morand about #Anifrolumab in #SLE - the #TULIP-2 study - whilst preparing for the turn of the year.
Trial of Anifrolumab in Active Systemic Lupus Erythematosus | NEJM https://t.co/LgZfvwHsF2
RT @NEJM: Original Article: Trial of Anifrolumab in Active Systemic Lupus Erythematosus https://t.co/PwZnsYSu2F
Trial of Anifrolumab in Active Systemic Lupus Erythematosus | NEJM https://t.co/JcDg87CC1p
RT @FAndreMD: 18 years after the discovery that type I interferon is a key molecular target in patients with lupus (Blanco, Science, 2001),…
RT @NEJM: Original Article: Trial of Anifrolumab in Active Systemic Lupus Erythematosus https://t.co/PwZnsYSu2F
RT @NEJM: Original Article: Trial of Anifrolumab in Active Systemic Lupus Erythematosus https://t.co/PwZnsYSu2F
RT @FAndreMD: 18 years after the discovery that type I interferon is a key molecular target in patients with lupus (Blanco, Science, 2001),…
RT @FAndreMD: 18 years after the discovery that type I interferon is a key molecular target in patients with lupus (Blanco, Science, 2001),…
RT @NEJM: Original Article: Trial of Anifrolumab in Active Systemic Lupus Erythematosus https://t.co/PwZnsYSu2F
RT @NEJM: Original Article: Trial of Anifrolumab in Active Systemic Lupus Erythematosus https://t.co/PwZnsYSu2F
RT @NEJM: Original Article: Trial of Anifrolumab in Active Systemic Lupus Erythematosus https://t.co/PwZnsYSu2F
https://t.co/jelgrJ9t0T
RT @NEJM: Original Article: Trial of Anifrolumab in Active Systemic Lupus Erythematosus https://t.co/PwZnsYSu2F
RT @NEJM: Original Article: Trial of Anifrolumab in Active Systemic Lupus Erythematosus https://t.co/PwZnsYSu2F
RT @FAndreMD: 18 years after the discovery that type I interferon is a key molecular target in patients with lupus (Blanco, Science, 2001),…
RT @FAndreMD: 18 years after the discovery that type I interferon is a key molecular target in patients with lupus (Blanco, Science, 2001),…
RT @FAndreMD: 18 years after the discovery that type I interferon is a key molecular target in patients with lupus (Blanco, Science, 2001),…
RT @FAndreMD: 18 years after the discovery that type I interferon is a key molecular target in patients with lupus (Blanco, Science, 2001),…
18 years after the discovery that type I interferon is a key molecular target in patients with lupus (Blanco, Science, 2001), a randomized trial shows that Anifrolumab is effective in SLE. A very good illustration of translational science https://t.co/2mXHYHeAtZ
RT @NEJM: Original Article: Trial of Anifrolumab in Active Systemic Lupus Erythematosus https://t.co/ddcp8ZzOcb
RT @NEJM: Original Article: Trial of Anifrolumab in Active Systemic Lupus Erythematosus https://t.co/PwZnsYSu2F
RT @NEJM: Original Article: Trial of Anifrolumab in Active Systemic Lupus Erythematosus https://t.co/PwZnsYSu2F
RT @NEJM: Original Article: Trial of Anifrolumab in Active Systemic Lupus Erythematosus https://t.co/PwZnsYSu2F
RT @NEJM: Original Article: Trial of Anifrolumab in Active Systemic Lupus Erythematosus https://t.co/PwZnsYSu2F
RT @NEJM: Original Article: Trial of Anifrolumab in Active Systemic Lupus Erythematosus https://t.co/PwZnsYSu2F
RT @NEJM: Original Article: Trial of Anifrolumab in Active Systemic Lupus Erythematosus https://t.co/PwZnsYSu2F
RT @NEJM: Original Article: Trial of Anifrolumab in Active Systemic Lupus Erythematosus https://t.co/PwZnsYSu2F
RT @NEJM: Original Article: Trial of Anifrolumab in Active Systemic Lupus Erythematosus https://t.co/PwZnsYSu2F
RT @NEJM: Original Article: Trial of Anifrolumab in Active Systemic Lupus Erythematosus https://t.co/PwZnsYSu2F
RT @NEJM: Original Article: Trial of Anifrolumab in Active Systemic Lupus Erythematosus https://t.co/PwZnsYSu2F
RT @NEJM: Original Article: Trial of Anifrolumab in Active Systemic Lupus Erythematosus https://t.co/PwZnsYSu2F
RT @NEJM: Original Article: Trial of Anifrolumab in Active Systemic Lupus Erythematosus https://t.co/PwZnsYSu2F
RT @NEJM: Original Article: Trial of Anifrolumab in Active Systemic Lupus Erythematosus https://t.co/PwZnsYSu2F
RT @NEJM: Original Article: Trial of Anifrolumab in Active Systemic Lupus Erythematosus https://t.co/PwZnsYSu2F
RT @NEJM: Original Article: Trial of Anifrolumab in Active Systemic Lupus Erythematosus https://t.co/PwZnsYSu2F
Original Article: Trial of Anifrolumab in Active Systemic Lupus Erythematosus https://t.co/PwZnsYSu2F
Trial of Anifrolumab in Active Systemic #Lupus Erythematosus | NEJM https://t.co/EEoGUDMrYb
Trial of Anifrolumab in Active Systemic Lupus Erythematosus | NEJM https://t.co/UFiMNus5hV https://t.co/XdLRrvRbNK
RT @Lupus_bio: Trial of Anifrolumab in Active Systemic Lupus Erythematosus.: Anifrolumab a human monoclonal antibody to type I interferon r…
Trend new: *Morand EF* et al (N Engl J Med) __Trial of Anifrolumab in Active Systemic Lupus Erythematosus.__ https://t.co/5JVN0RW4XQ
Trend up+2: *Morand EF* et al (N Engl J Med) __Trial of Anifrolumab in Active Systemic Lupus Erythematosus.__ https://t.co/5JVN0RW4XQ
Hmmmm. Wait & see I guess. Trial of Anifrolumab in Active Systemic Lupus Erythematosus | NEJM https://t.co/RBdI221vII
Trend new: *Morand EF* et al (N Engl J Med) __Trial of Anifrolumab in Active Systemic Lupus Erythematosus.__ https://t.co/5JVN0RW4XQ
Trial of Anifrolumab in Active Systemic Lupus Erythematosus.: Anifrolumab a human monoclonal antibody to type I interferon receptor subunit 1 investigated for the treatment of systemic lupus erythematosus SLE did not have a significant effect on the… https://t.co/wZnSUA05lk
Trial of Anifrolumab in Active Systemic Lupus Erythematosus https://t.co/zDlq01URxj
RT @HofstraKidney: Richard Furie from our Rheumatology Division @NEJM Trial of Anifrolumab in Active Systemic Lupus Erythematosus https://t…
Trial of Anifrolumab in Active Systemic Lupus Erythematosus | NEJM https://t.co/FeDaA5qISM
RT @HofstraKidney: Richard Furie from our Rheumatology Division @NEJM Trial of Anifrolumab in Active Systemic Lupus Erythematosus https://t…
RT @caminalm: Trial of Anifrolumab in Active Systemic Lupus Erythematosus | NEJM https://t.co/Kj8K36XLFW
RT @LuisAlvarezRa: Trial of Anifrolumab in Active Systemic Lupus Erythematosus | NEJM https://t.co/nxiIB9f7kY
Trial of Anifrolumab in Active Systemic Lupus Erythematosus. https://t.co/PGz4DTbK1t
Trial of Anifrolumab in Active Systemic Lupus Erythematosus | NEJM https://t.co/kUW4UzlGJJ
Trial of Anifrolumab in Active Systemic Lupus Erythematosus | NEJM https://t.co/nxiIB9f7kY
RT @HofstraKidney: Richard Furie from our Rheumatology Division @NEJM Trial of Anifrolumab in Active Systemic Lupus Erythematosus https://t…
علاج فعال في حلات الذئبة الحمراء antibody to type I interferon receptor is an effective treatment for SLE Trial of Anifrolumab in Active Systemic Lupus Erythematosus | NEJM https://t.co/Sod1q4wOfm
RT @HofstraKidney: Richard Furie from our Rheumatology Division @NEJM Trial of Anifrolumab in Active Systemic Lupus Erythematosus https://t…
Richard Furie from our Rheumatology Division @NEJM Trial of Anifrolumab in Active Systemic Lupus Erythematosus https://t.co/iCBv3q0ow7
Richard Furie from our Rheumatology Division @NEJM Trial of Anifrolumab in Active Systemic Lupus Erythematosus https://www.nejm.org/doi/full/10.1056/NEJMoa1912196#.XftQ7c95Swc.twitter
Trial of Anifrolumab in Active Systemic Lupus Erythematosus | NEJM https://t.co/Kj8K36XLFW
Trial of Anifrolumab in Active Systemic Lupus Erythematosus | NEJM https://t.co/dRGSUus2xD
マブは追いつけなくなってきました。SLE治療薬、Ⅰ型インターフェロン受容体抗体、アニフロマブ anifromabのRCT。#SLE Trial of Anifrolumab in Active Systemic Lupus Erythematosus | NEJM https://t.co/bAMZr0w2YH
Trial of Anifrolumab in Active Systemic Lupus Erythematosus. N Engl J Med 2020; 382(3): 211–221, doi: 10.1056/NEJMoa1912196. 46. Henze L, Buhl ...
doi: 10.1056/NEJMOA1912196. 14. Liu W, Li M, Wang Z, Wang J. IFN-γ mediates the development of systemic lupus erythematosus. Biomed Res Int. 2020;2020 ...
org/doi/full/10.1056/nejmoa1912196）。Biogenのこの新薬は皮膚SLEを標的化したものだが、感染症はインターフェロン抑制薬のクラス有害効果である。 関連する ...
לופוס זאבת Lupus עמותת עינבר. 1563 likes · 4 talking about this. עמותה ישראלית לנפגעים במחלות ראומטיות, אוטואימוניות ודלקתיות וארגון הלופוס הישראלי
The New England Journal of Medicine. December 18, 2019. Doi: 10.1056/NEJMoa1912196. No photo description available. Leonardo Vitor Silva and 26 others ·
https://doi.org/10.1056/NEJMOA1912196. 14. Liu W, Li M, Wang Z, Wang J. IFN-γ mediates the development of systemic lupus erythematosus ...
The New England Journal of Medicine. 2020;382(3):211-221. doi:10.1056/NEJMoa1912196.
N Engl J Med 2020; 382(3): 211–221, doi: 10.1056/NEJMoa1912196. 46. Henze L, Buhl C, Sandherr M, et al. Management of herpesvirus ...
doi:10.1056/NEJMoa1912196; Rovin BH, Teng YKO, Ginzler EM, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis ...
org/doi/full/10.1056/nejmoa1912196 19.Furie R, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP ...
Morand EF et al., NEJM 2020; doi: 10.1056/NEJMoa1912196 · Augustin M et al., Acta Derm Ven 2022; https://doi.org/10.1111/jdv.18168 · Blauvelt A ...
doi:10.1056/NEJMoa1912196; Brown DR, Fouad MN, Based-Engquist MA, et al. Recruitment and retention of minority women in cancer screening ...
DOI: 10.1056/NEJMoa1912196. Epub 2019 Dec 18. PMID: 31851795. 3: Koichiro Ohmura (2021) Which is the best SLE activity index for clinical ...
Мне нравится, что в клинические испытания 3 фазы анифролумаба](https://www.nejm.org/doi/full/10.1056/nejmoa1912196) (Saphnelo) включили ...
org/doi/full/10.1056/nejmoa1912196. nejm.org. Trial of Anifrolumab in Active Systemic Lupus Erythematosus |. 4 yrs. Recent Posts. Организация на ...
org/doi/full/10.1056/nejmoa1912196. 特别声明：本文为网易自媒体平台“网易号”作者上传并发布，仅代表该作者观点。网易仅提供信息发布平台。 Notice ...
... Systemic Lupus Erythematosus. N Engl J Med, 10.1056/NEJMoa1912196. 平台声明. 评论. 全部. 还没有人评论过，快来抢首评. 抢首评. 微信好友; 朋友圈; QQ ...
N Engl J Med, 2020; 382, DOI: 10.1056/NEJMoa1912196. 13.Safety and efficacy of two doses of anifrolumab compared to placebo in adult subjects ...
The New England Journal of Medicine. 2020;382(3):211-221. doi:10.1056/NEJMoa1912196.
2019;doi:10.1056/NEJMoa1912196. For more information: Leonard A. Calabrese, DO, can be reached at 9500 Euclid Ave., Cleveland, Ohio 44195 ...
פירמידת הטיפולים למחלת הזאבת. מאורח חיים בריא ועד IVIG. פרופ' גודארד נותנת לנו סקירת טיפולים עדכנית וגם הצצה לעתיד עם מחקר של תרופה חדשה.
10 likes, 0 comments - romatoloji.klinigi on January 25, 2020: "Sistemik #lupus Eritematozus kadınlarda tedavisinde yeni bir potansiyel ...
Abstract BACKGROUND Anifrolumab, a human monoclonal antibody to type I interferon receptor subunit 1 investigated for the treatment of ...
2019;doi:10.1056/NEJMoa1912196. Healio AI. Ask a clinical question and tap into Healio AI's knowledge base. PubMed, enrolling/recruiting ...
org/ 10.1056/NEJMoa1912196. 《中国科学报》 (2019-12-24 第2版国际). 打印 发E-mail给：. 以下评论只代表网友个人观点，不代表科学网观点。 相关新闻 ...
Das zeigt eine im New England Journal of Medicine publizierte Studie (2019; DOI: 10.1056/NEJMoa1912196). In der Parallelstudie in Lancet ...
doi: 10.1056/nejmoa1912196, https://www.nejm.org/doi/full/10.1056/NEJMoa1912196. Currently rated 5.0 by 1 person. Posted in: Medical Research ...
New England Journal of Medicine DOI: 10.1056/NEJMoa1912196. Topics: immune system. Advertisement. Sign up to our weekly newsletter. Receive a ...
N
F
AD
CB
C
SI
PB
CW
فا
YE
MM
AS
CG
MM
DD
鯵C
DM
SA
HR
CZ
JM
M
JL
دA
帝R
MA
SB
JF
SM
X
RC
SB
KC
RC
ML
KM
DM
CE
UR
N
CE
M
AP
P
CM
U
RP
TM
RC
م
LM
LJ
LS
VB
SU
A
PM
LN
RF
散
DV
JS
FC
I
PK
R
ノม
JM
TP
L
SM
L
OE
C
XL
病結
CB
ST
官H
JL
E
IC
BM
GV
SH
AS
SA
IM
MO
IM
JO
O
JS
JJ
FL
AM
C
S
FP
FB
PF
SA
CP
D
JC
HA
Sর
RB
GS
G
DC
DF
W
R
M
D
LC
LN
TL
LF
AH
JM
MM
SS
CB
LA
AM
دH
KJ
HK
LC
JR